Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
JAK inhibitors work — and broadly. Multiple real-world studies confirm that JAK inhibitors significantly reduce disease activity and improve quality of life in rheumatoid arthritis patients, regardless of age, diabetes status, or cardiometabolic burden. Risk-based patient selection following 2022 safety guidelines has also been linked to safer outcomes, with no major cardiovascular or thromboembolic events reported post-implementation.
Three real-world studies paint a consistent and encouraging picture for JAK inhibitor use in rheumatoid arthritis (RA). The largest — a 440-patient Italian multicenter study — found that JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) significantly cut disease activity over 12 months, with mean DAS28-CRP scores dropping from 3.9 to 2.4 and SDAI scores falling from 19.8 to 8.1. Crucially, effectiveness and safety held steady regardless of whether patients had type 2 diabetes, cardiometabolic multimorbidity, or were aged 65+.
A French study of 120 RA patients further showed strong long-term treatment persistence and highlighted that following the 2022 PRAC safety recommendations — restricting use in higher-risk patients — eliminated major cardiovascular and thromboembolic events. A Japanese registry study added that reduced-dose JAK inhibitor initiation in patients with preserved kidney function achieved comparable 2-year persistence and disease control to standard dosing.
Why it matters: These findings reinforce JAK inhibitors as a broadly effective RA treatment in routine clinical practice — even in older or metabolically complex patients. The post-PRAC safety data also support individualized, risk-stratified prescribing as a practical way to maximize benefit while minimizing serious harm.
